Berger Amnon A, Syed Zuby, Ryan Lianne, Lee Christopher, Hasoon Jamal, Urits Ivan, Viswanath Omar, Cornett Elyse M, Kaye Alan D, Eskander Jonathan P
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Department of Medicine, Georgetown University School of Medicine, Washington DC.
Orthop Rev (Pavia). 2022 Apr 25;14(3):31921. doi: 10.52965/001c.31921. eCollection 2022.
The purpose of this study is to determine if using a combination of dexamethasone and dexmedetomidine (Dex-Dex) in a single-shot perineural local anesthestic provides an increased duration of pain relief and reduced consumption of opioids for patients undergoing shoulder surgery.
This is a retrospective trial of adult patients without major comorbidities undergoing elective, upper arm orthopedic procedures with regional nerve block for post-operative analgesia. Patients underwent nerve block with either 0.5% ropivacaine or 0.2% ropivacaine with 5mg dexamethasone and 25mg dexmedetomidine ("dex-dex"). Patients were assessed in 1-week intervals for two weeks for duration of block analgesia, pain scores, and opioid use.
31 patients were included, 12 controls and 19 in the dex-dex group. These patients underwent one of arthroscopic rotator cuff repair, reverse total shoulder repair or repair of humerus fractures. Dex-dex blocks provided significantly longer analgesia (median block time 3.5 versus 1.5 days, p<0.0001), significantly better analgesia (mean NRS 2.32 versus 8.58 on post-operative day 1, p<0.0001), and significantly reduced opioid requirements (108.16mg vs 275.63mg in MME, p<0.0001). One patient experienced transient hypotension and prolonged paresthesia in the dex-dex group.
Preoperative single-shot interscalene nerve blocks with preservative-free dexamethasone and dexmedetomidine added as adjuvants to ropivicaine provide approximately two additional days of benefit versus ropivicaine alone. Additionally, postoperative opioid consumption is reduced.
本研究的目的是确定在单次神经周围局部麻醉中使用地塞米松和右美托咪定的组合(地塞米松-右美托咪定)是否能延长接受肩部手术患者的疼痛缓解时间并减少阿片类药物的使用量。
这是一项针对无重大合并症的成年患者的回顾性试验,这些患者接受择期上臂骨科手术,并采用区域神经阻滞进行术后镇痛。患者接受了0.5%罗哌卡因或添加5mg地塞米松和25mg右美托咪定(“地塞米松-右美托咪定”)的0.2%罗哌卡因进行神经阻滞。在两周内每隔1周对患者进行一次评估,评估内容包括阻滞镇痛的持续时间、疼痛评分和阿片类药物的使用情况。
共纳入31例患者,其中12例为对照组,19例为地塞米松-右美托咪定组。这些患者接受了关节镜下肩袖修复、反式全肩关节置换或肱骨骨折修复手术之一。地塞米松-右美托咪定阻滞提供了显著更长的镇痛时间(中位阻滞时间3.5天对1.5天,p<0.0001)、显著更好的镇痛效果(术后第1天平均数字评定量表评分2.32对8.58,p<0.0001),并且显著减少了阿片类药物的需求量(吗啡毫克当量为108.16mg对275.63mg,p<0.0001)。地塞米松-右美托咪定组有1例患者出现短暂性低血压和持续性感觉异常。
术前在罗哌卡因中添加无防腐剂的地塞米松和右美托咪定进行单次肌间沟神经阻滞,与单独使用罗哌卡因相比,可额外提供约两天的益处。此外,术后阿片类药物的使用量减少。